5 Cheap Biotech Stocks Smart Investors Are Piling Into

3. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Investors In Q2 2023: 45

P/E Ratio: 13.13

United Therapeutics Corporation (NASDAQ:UTHR) is a Maryland based firm that focuses on treatments and aids for lung capacity and lung diseases. The firm has beaten analyst EPS estimates in three of its four latest quarters and the stock is rated Buy on average.

During this year’s June quarter, 45 out of the 910 hedge funds tracked by Insider Monkey were United Therapeutics Corporation (NASDAQ:UTHR)’s shareholders. Out of these, Kurt Von Emster’s VenBio Select Advisor owns the largest stake which is worth $642 million.

Follow United Therapeutics Corp (NASDAQ:UTHR)